USA flag logo/image

An Official Website of the United States Government

DEVELOPMENT OF PALYTOXIN IMMUNOTOXINS PHASE I

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
495
Program Year/Program:
1984 / SBIR
Agency Tracking Number:
495
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
HAWAII BIOTECH, INC.
99-193 AIEA HEIGHTS DRIVE, SUITE 200 AIEA, HI -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 2
Fiscal Year: 1984
Title: DEVELOPMENT OF PALYTOXIN IMMUNOTOXINS PHASE I
Agency: HHS
Contract: N/A
Award Amount: $500,000.00
 

Abstract:

THE OBJECTIVE OF THIS PROJECT IS TO ESTABLISH METHODS FOR CONJUGATING THE POTENT MARINE TOXIN, PALYTOXIN TO ANTIBODIES IN SUCH A WAY THAT SPECIFIC CYTOTOXICITY OF TARGET CELLS IS POSSIBLE. THE PRODUCT, IMMUNOPALYTOXIN (IPT), SHOULD BE EASILY PREPARED, HAVE HIGH SPECIFIC CYTOTOXIC ACTIVITY AND BE MINIMALLY TOXIC TO UNRELATED CELLSOR INTACT ANIMALS. THIS WORK WILL INVESTIGATE CHEMICAL LINKAGES BETWEEN PALYTOXIN AND ANTIBODIES AND CHARACTERIZE THE RESULTANT PRODUCT. ALL CYTOTOXICITY TESTING WILL BE CONDUCTED IN VITRO USING LYMPHOID CELL LINES. ANTIBODIES WILL BE USED WHICH RECOGNIZE SPECIFIC ANTIGENS ON THE TARGETCELLS. CYTOTOXICITY WILL BE MEASURED BY DYE EXCLUSION UPTAKE, PROTEIN SYNTHESIS AND CELL GROWTH CAPACITIES AFTER EXPOSURE TO IPT. SUCCESSFUL PRODUCTION OF IPT WHICH MEETS OUR DESIGN CRITERIA WILL HAVE APPLICATION IN BIOMEDICAL SITUATIONS WHERE SPECIFIC CYTOTOXICITY IS DESIRED. THERAPY OF CANCER, MODULATION OF IMMUNE RESPONSES, AND SPECIFIC CELLABLATION ARE IMPORTANT EXAMPLES OF HOW THIS PRODUCT COULD BEUSED. THE RESULTS OF THIS PHASE I PROJECT WILL LAY THE GROUNDWORK FOR IN VITRO TESTS IN ANIMALS AND, ULTIMATELY, HUMAN CLINICAL APPLICATIONS.

Principal Investigator:

Douglas C. Vann, Ph.d.
8084875561

Business Contact:

Small Business Information at Submission:

Hawaii Biotechnology Group Inc
99-193 Aiea Heights Drive Aiea, HI 96701

EIN/Tax ID:
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No